All Pharmaceutical manufacturers articles
-
ArticleDistilling compliance lessons from healthcare fraud cases
False Claims Act recoveries related to healthcare fraud in fiscal year 2018 offer key insight into the best practices the government expects to ensure compliance with federal healthcare laws.
-
Blog
FDA will publicly scold drug companies that try to derail generics
The FDA’s new tactic for driving down prescription drug costs: publicly shaming them by “shining a light on situations where drug makers may be pursuing gaming tactics to delay generic competition.” Drug companies that try to scuttle generic competition will be named on the FDA’s Website.
-
Article
Enforcement against opioid drug makers and distributors escalates
Several actions taken by the Department of Justice in recent weeks make it clear that prosecutors have their sights set squarely on pharmaceutical manufacturers and distributors for their role in the opioid epidemic.
-
ArticleThe compliance side of the war on drugs
In a precedent-setting case, drugmaker Mallinckrodt Pharmaceuticals has agreed to a $35 million settlement with the U.S. federal government for failing to monitor its sales channels for suspicious orders.